1. Neocrema’s Q2 Performance: What Happened?

Neocrema posted impressive results for Q2 2025, recording sales of KRW 21.4 billion, operating profit of KRW 3.2 billion, and net income of KRW 1.4 billion, marking a successful return to profitability. This significantly exceeded market expectations, attracting substantial investor interest.

2. The Secret to Neocrema’s Turnaround

The surge in exports within the functional peptide segment played a pivotal role in Neocrema’s impressive performance. The 88.5% year-over-year increase in exports translated into higher profitability, driving the shift to positive operating income. Continuous cost reduction efforts and a robust financial structure further contributed to the positive results.

3. Neocrema’s Future Outlook

  • Positive Factors: Continued growth in the functional peptide segment, new business expansions, and sound financial health.
  • Risk Factors: Decline in product sales, foreign exchange volatility, and potential increased competition.

While Neocrema shows significant growth potential, primarily driven by the functional peptide segment, investors should consider potential risks such as fluctuations in product sales, currency exchange rates, and intensifying competition.

4. Action Plan for Investors

While Neocrema’s Q2 results are encouraging, consider the following before making investment decisions:
1. Verify the sustained growth potential of the functional peptide segment.
2. Monitor the progress and performance of new business ventures.
3. Analyze macroeconomic changes and the competitive landscape.
Thorough due diligence is crucial for making informed investment choices.